The Ambroxol ASPro-PD trial is an innovative Phase 2/3 clinical trial evaluating ambroxol, a mucolytic drug that has shown promise as a disease-modifying treatment for Parkinson's disease. This trial specifically focuses on ambroxol's ability to increase glucocerebrosidase (GCase) activity, addressing a key genetic pathway implicated in Parkinson's disease pathogenesis[@ambroxol2022][@gba2021].
Ambroxol represents a drug repurposing approach, taking advantage of an existing medication with a known safety profile to target a novel therapeutic pathway in Parkinson's disease. The ASPro-PD (Ambroxol Study in Parkinson's Disease) trial represents one of the most advanced efforts to bring a GCase-enhancing therapy to clinical application for Parkinson's disease patients[@ambroxol2024].
| Attribute |
Value |
| NCT Number |
NCT05827068 |
| Phase |
Phase 2/3 |
| Status |
Active, Recruiting |
| Sponsor |
University of Manchester / Parkinson's UK |
| Patient Population |
Parkinson's disease with GBA1 variants or idiopathic PD |
| Duration |
Approximately 2 years |
| Enrollment |
Target 200 participants |
| Primary Endpoint |
24 months |
| Start Date |
2023 |
| Expected Completion |
2026 |
| Arm |
Intervention |
Dose |
Route |
| 1 |
Ambroxol |
1260 mg/day (split dosing) |
Oral |
| 2 |
Placebo |
N/A |
Oral |
| 3 |
Ambroxol (extension) |
1260 mg/day |
Oral |
The trial uses a 1:1 randomization ratio between active treatment and placebo, with an optional open-label extension for participants completing the blinded phase.
Mutations in the GBA1 gene (glucocerebrosidase) represent the most common genetic risk factor for Parkinson's disease known to date. The relationship between GBA1 mutations and PD was first identified in 2009 and has since been validated in multiple populations worldwide.
Epidemiology of GBA1-Associated PD:
- Heterozygous GBA1 mutations: Increase PD risk 5-20 fold depending on specific mutation
- Prevalence: 5-10% of PD patients carry GBA1 mutations
- Age of onset: Typically 5-10 years earlier than idiopathic PD
- Clinical phenotype: More rapid progression, earlier cognitive impairment
The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme responsible for breaking down glucosylceramide into glucose and ceramide. In GBA1 mutation carriers, the enzyme activity is reduced, leading to accumulation of its substrate[@gba2021].
¶ GCase and Alpha-Synuclein: A Vicious Cycle
The relationship between GCase and alpha-synuclein is bidirectional and creates a self-reinforcing pathological cycle that drives neurodegeneration[@gcase2023]:
- Reduced GCase activity leads to glucosylceramide accumulation in neurons
- Glucosylceramide directly promotes alpha-synuclein aggregation
- Aggregated alpha-synuclein inhibits GCase trafficking and function
- Inhibited GCase results in more glucosylceramide accumulation
- This cycle continues, progressively impairing neuronal function
This bidirectional relationship means that even in idiopathic PD (without GBA1 mutations), the GCase-alpha-synuclein interaction may contribute to disease pathogenesis, making GCase enhancement a therapeutic strategy applicable to a broad PD population.
Ambroxol, originally developed as a mucolytic for respiratory conditions, has been used clinically for over 50 years:
- Known Safety Profile: Extensive clinical use has established a well-characterized safety profile at high doses
- Blood-Brain Barrier Penetration: Demonstrated CNS penetration in humans
- GCase Enhancement: Multiple preclinical and clinical studies show activity as a pharmacological chaperone
- Established Manufacturing: Generic availability reduces development costs
The drug repurposing approach offers significant advantages in terms of development timeline and regulatory pathways, as extensive safety data already exists from decades of clinical use.
Ambroxol (2-amino-3,5-dibromo-4-methoxybenzylamine) acts through multiple mechanisms relevant to Parkinson's disease pathogenesis[@ambroxol2019]:
Ambroxol acts as a pharmacological chaperone for GCase:
- Binding: Binds to the active site of GCase, stabilizing the enzyme structure
- Folding assistance: Helps proper folding of mutant GCase molecules in the endoplasmic reticulum
- Lysosomal trafficking: Facilitates transport through the secretory pathway to lysosomes
- Enzyme stabilization: Protects against degradation and increases lysosomal activity
- Substrate reduction: Enhanced GCase activity reduces glucosylceramide accumulation
The chaperone activity extends to alpha-synuclein regulation:
- Aggregation inhibition: Reduces glucosylceramide-induced alpha-synuclein aggregation
- Clearance promotion: Enhances autophagy-mediated clearance of protein aggregates
- Breaking the cycle: May interrupt the GCase-alpha-synuclein pathological loop
Ambroxol exhibits several additional mechanisms:
- Anti-inflammatory effects: Reduces microglial activation and neuroinflammation
- Antioxidant properties: Scavenges reactive oxygen species
- Neurotrophic factor expression: May promote expression of protective growth factors
- Lysosomal function enhancement: Improves overall lysosomal health
The pharmacokinetic profile supports once-daily or split-dosing:
- Absorption: Rapid oral absorption with peak plasma concentrations at 1-3 hours
- Distribution: Wide tissue distribution including the CNS
- Metabolism: Hepatic metabolism through cytochrome P450 enzymes
- Half-life: Approximately 10-12 hours supporting daily dosing
- Excretion: Primarily renal elimination
Multiple preclinical studies support the GCase-enhancing activity of ambroxol:
- Cell culture studies: Showed dose-dependent GCase activity increase in neurons
- Animal models: Demonstrated reduced alpha-synuclein aggregation in mouse models
- Pharmacokinetic studies: Confirmed brain penetration at therapeutic doses
- Toxicology studies: Established maximum tolerated doses for chronic dosing
A landmark study published in Brain demonstrated[@ambroxol2019]:
- Study design: Single-dose escalation in 12 PD patients (6 GBA1 carriers, 6 non-carriers)
- Dosing: Up to 1260 mg/day for 6 months
- Primary outcome: GCase activity in peripheral blood mononuclear cells (PBMCs)
- Results: 35% increase in GCase activity in PBMCs
- Safety: Well-tolerated with no serious adverse events
Multiple open-label studies confirmed the findings:
- 24-week study: Showed sustained GCase enhancement
- Biomarker changes: Reduced glucosylceramide levels in some patients
- Cognitive signals: Some patients showed cognitive stabilization
- Motor outcomes: Mixed results, not powered for efficacy
The 12-month open-label extension provided[@ambroxol2024]:
- Sustained GCase activity: Continued enzyme enhancement through 12 months
- Safety profile: No new safety signals with long-term use
- Clinical outcomes: Encouraging trends in motor and non-motor symptoms
- Biomarker data: Validation of target engagement in CSF
The ASPro-PD trial employs a rigorous adaptive design:
- Initial Phase: Dose-finding and initial efficacy signal
- Seamless transition: Early transition to confirmatory phase
- Adaptive elements: Sample size re-estimation based on interim results
-
Primary Efficacy:
- Change in MDS-UPDRS (Parts I+II+III) total score at 24 months
- Time to clinically meaningful progression
-
Primary Safety:
- Adverse event incidence and severity
- Discontinuation rate
- Serious adverse events
- Motor symptoms: MDS-UPDRS Part III (motor examination)
- Functional status: MDS-UPDRS Part II (motor aspects of experiences of daily living)
- Non-motor symptoms: PDQ-39, MoCA, Epworth Sleepiness Scale
- Disease progression: Hoehn & Yahr staging
- GCase activity: In peripheral blood mononuclear cells
- Glucosylceramide: Plasma and CSF levels
- Alpha-synuclein: CSF concentration and seeding activity
- Neurofilament light chain (NfL): Plasma and CSF
- ** tau and p-tau181:** CSF neurodegenerative markers
- DAT PET: Dopamine transporter binding
- MRI: Brain volume measurements
- Transcranial sonography: Substantia nigra hyperechogenicity
The trial employs a biomarker-driven enrichment approach:
- GBA1 carriers: Direct targeting of the mechanism
- Idiopathic PD: Alpha-synuclein seed amplification assay (PMCA) positivity
- Rationale: Ensures patients with relevant biology are enrolled
This enrichment strategy increases the probability of detecting a treatment effect by selecting patients most likely to benefit from GCase enhancement.
- Age: 30-80 years
- PD diagnosis: UK Brain Bank criteria
- Disease duration: 1-10 years
- Hoehn & Yahr stage: 1-3 (inclusive)
- Medication stability: Stable PD medication for 4+ weeks
- Genetic eligibility (one of):
- Confirmed pathogenic GBA1 variant (heterozygous), OR
- Idiopathic PD with positive alpha-synuclein seed amplification assay (PMCA)
- Capacity: Able to provide informed consent
- Atypical parkinsonism: Progressive supranuclear palsy, multiple system atrophy, etc.
- Significant cognitive impairment: MMSE <24
- Active psychiatric disease: uncontrolled depression, psychosis
- Severe medical conditions: Cardiac, hepatic, renal, or hematologic
- Contraindications: MRI or PET incompatibilities
- Previous ambroxol: Prior participation in ambroxol PD trials
- Pregnancy: Active pregnancy or breastfeeding
- Substance abuse: Active alcohol or drug dependence
¶ Sample Size and Power
With 200 participants (100 per arm):
- Power: 80% power to detect 30% slowing of progression
- Assumption: 20-point difference in MDS-UPDRS at 24 months
- Alpha: 0.05 (two-sided)
- Dropout rate: 15% adjustment
- Intention-to-treat (ITT): All randomized participants
- Per-protocol: Participants meeting all eligibility criteria
- Biomarker-positive: Enrichment population analyses
¶ Multiple Comparison Handling
- Primary analysis: Hochberg procedure for primary and key secondary
- Hierarchical testing: Strong control of family-wise error rate
- Sensitivity analyses: Various imputation approaches for missing data
The ASPro-PD trial represents several important advances in Parkinson's disease therapeutics[@silva2024]:
- Disease Modification Target: First large trial targeting GCase to modify disease course
- Precision Medicine: Biomarker-based patient selection
- Drug Repurposing: Demonstrates value of finding new uses for old drugs
- Genetic Discovery Translation: Direct translation from genetic discovery to therapy
- Bidirectional Mechanism: Targets the GCase-alpha-synuclein pathological cycle
Positive results would establish:
- New therapeutic class: First approved GCase-enhancing therapy
- Broad applicability: Both GBA1-associated and idiopathic PD
- Disease modification: Potential to slow progression, not just treat symptoms
- Combination potential: Could be combined with other PD therapies
¶ Challenges and Considerations
Several challenges remain:
- Dose optimization: Determining optimal CNS-active dose
- Biomarker validation: Confirming target engagement in brain
- Patient variability: Different GCase response among patients
- Clinical endpoint sensitivity: Detecting subtle progression differences
- Long-term effects: Unknown effects beyond 2 years
¶ Competitive Landscape
| Therapy |
Company |
Mechanism |
Stage |
| Ambroxol |
University of Manchester |
Pharmacological chaperone |
Phase 2/3 |
| Venglustat |
Sanofi |
GCase substrate reduction |
Phase 2 (stopped) |
| LTI-291 |
Luc Therapeutics |
GCase activator |
Phase 1 |
| ABM-001 |
Aprinoia |
GCase modulator |
Preclinical |
- Established safety profile from decades of use
- Oral administration vs. infusion
- Broad applicability beyond GBA1 carriers
- Lower development costs
Pharmacological chaperones represent a unique therapeutic modality that differs from traditional enzyme replacement or small molecule inhibition approaches.
Chaperones work through multiple mechanisms:
- Stabilization Binding
- Pre-mature enzyme binding stabilizes structure
- Allows proper folding in the ER
- Facilitates lysosomal trafficking
- Increases enzyme half-life
| Binding Type |
Mechanism |
Example |
| Competitive |
Active site binding |
Migalastat (Fabry disease) |
| Allosteric |
Conformational sites |
Ambroxol (PD) |
The effect on enzyme activity follows specific kinetics:
- Substrate Binding: Reduced (competitive inhibition at high substrate)
- Protein Stability: Increased half-life
- Trafficking: Enhanced lysosomal delivery
- Catalytic Efficiency: Improved turnover
| Feature |
Function |
Impact |
| Molecular weight < 500 Da |
Passive diffusion |
Essential |
| LogP 1-3 |
Optimal BBB penetration |
Important |
| Low polar surface area |
Membrane crossing |
Required |
| Amine group |
Lysosomal concentration |
Key feature |
The ambroxol structure enables:
- BBB Crossing: Moderate lipophilicity
- Lysosomal Accumulation: Ion trapping at acidic pH
- Protein Binding: GCase interaction
- Safety: Decades of clinical use
| Year |
Event |
Regulatory Impact |
| 2019 |
First clinical proof-of-concept |
Established safety |
| 2021 |
GBA1 subset data |
Precision selection |
| 2023 |
Phase 2/3 start |
IND clearance |
| 2024 |
12-month data |
Publications |
| 2026 |
Primary completion |
NDA filing |
- Fast Track Designation: Received for GBA1+ PD
- Breakthrough Therapy: Under consideration
- Orphan Drug: Not pursued (too common)
If approved, ambroxol would be indicated for:
-
Patient Selection
- GBA1 variant carriers
- Idiopathic PD with biomarker+ status
- Early-to-moderate disease stage
-
Dosing Protocol
- 1260 mg/day (split BID)
- With or without food
- Can combine with dopaminergic therapy
-
Monitoring Schedule
| Visit |
Assessments |
| Baseline |
Full workup |
| Month 1 |
Safety, biomarkers |
| Month 6 |
Clinical, biomarkers |
| Month 12 |
Full assessment |
| Ongoing |
Annual |
| Drug Class |
Interaction |
Management |
| CYP3A4 inhibitors |
May increase levels |
Reduce dose |
| CYP3A4 inducers |
May decrease levels |
Monitor |
| Anticholinergics |
Additive effects |
Monitor |
| MAO-B inhibitors |
Safe combination |
Standard |
¶ Accessibility and Cost
Annual treatment economics:
| Cost Component |
Approximate |
| Medication |
$5,000-8,000 |
| Monitoring |
$3,000-5,000 |
| Clinical visits |
$2,000-4,000 |
| Total Annual |
$10,000-17,000 |
- Generic Availability: Potential post-patent
- Disease Modification: Reduced long-term care costs
- Quality of Life: Preserved independence
For disease modification claims:
-
Clinical Progression
- Slowed functional decline
- Maintained independence
- Reduced disability
-
Biomarker Stability
- Sustained GCase activity
- Reduced glucosylceramide
- Stable neurofilament
-
Neuroimaging
- Reduced dopamine loss
- Brain volume preservation
-
With Symptomatic Therapy
- Dopamine agonists
- MAO-B inhibitors
- Levodopa/carbidopa
-
With Other Disease-Modifying Agents
- Alpha-synuclein targeting
- Tau-modulating agents
- Antioxidants
Potential in pre-symptomatic individuals:
- GBA1 carriers: Early intervention
- Family screening: At-risk identification
- Biomarker-positive: Prevention trials
| Milestone |
Timeline |
Notes |
| Pre-IND |
Completed |
2018 |
| IND clearance |
2023 |
Phase 2/3 |
| Fast track |
2023 |
Granted |
| NDA filing |
2027 |
Expected |
| Approval |
2028 |
Projected |
Expected label:
- Indication: Parkinson's disease with GBA1 variant or biomarker+
- Dose: 1260 mg/day
- Monitoring: Regular assessments
- Duration: Chronic
| Region |
Status |
Timeline |
| USA |
Phase 2/3 |
2023-2027 |
| EU |
Phase 2/3 |
2023-2027 |
| UK |
Phase 2/3 |
2023-2026 |
| Japan |
Phase 2/3 |
2024-2028 |
Side effect profile and management:
| Aspect |
Reality |
Mitigation |
| Dosing |
BID |
Calendar reminder |
| Side Effects |
Mild GI |
With food |
| Monitoring |
Regular |
Integrated visits |
| Adherence |
High |
Simple regimen |
Expected benefits:
- Motor Function: Stabilization
- Non-Motor: Improved sleep, mood
- Independence: Prolonged
- Caregiver Burden: Reduced
-
University of Manchester
- Trial coordinators
- Clinical advice
- Research updates
-
Parkinson's UK
- Patient education
- Support groups
- Advocacy
-
International Networks
- Research partnerships
- Data sharing
- Best practices
-
Improved Target Engagement
- CNS GCase activity
- Brain glucosylceramide
- Regional imaging
-
Disease Staging
- Pre-symptomatic identification
- Treatment timing
- Response prediction
-
Enhanced Chaperones
- Higher potency
- Brain-penetrant
- Longer half-life
-
Gene Therapy Combinations
- GBA1 vector delivery
- Alpha-synuclein targeting
- Combined approach
Gene therapy approaches currently in development:
| Approach |
Vector |
Stage |
| AAV-GBA1 |
Adeno-associated virus |
Preclinical |
| Lentiviral |
Self-inactivating |
Discovery |
| mRNA delivery |
Lipid nanoparticles |
Discovery |
Gene therapy could provide:
- Sustained Expression: Long-term enzyme production
- CNS Targeting: Brain-specific promoters
- One-Time Treatment: Potential durability
¶ Summary and Key Takeaways
The ASPro-PD trial represents several important advances:
- Disease Modification Target: First large trial targeting GCase
- Precision Medicine: Biomarker-based patient selection
- Drug Repurposing: Demonstrates value of finding new uses for old drugs
- Genetic Discovery Translation: Direct translation from genetics to therapy
- Bidirectional Mechanism: Targets GCase-alpha-synuclein cycle
Positive results would establish:
- New Therapeutic Class: First approved GCase-enhancing therapy
- Broad Applicability: Both GBA1-associated and idiopathic PD
- Disease Modification: Potential to slow progression
- Combination Potential: Could be combined with other PD therapies
The development pathway includes:
- Phase 2/3 Results: Expected 2026
- NDA Submission: Target 2027
- Regulatory Decision: Expected 2028
- Post-Marketing: Long-term follow-up
- Unknown, Ambroxol for Parkinson's Disease: Rationale and Design (2022)
- Unknown, GBA1 Mutations in Parkinson's Disease (2021)
- Unknown, Ambroxol increases glucocerebrosidase activity in Parkinson's disease (2019)
- Unknown, Ambroxol in Parkinson's disease: 12-month results (2024)
- Unknown, Pharmacological chaperones for neurodegenerative diseases (2024)
- Unknown, Glucocerebrosidase and alpha-synuclein: A bidirectional relationship (2023)
- Unknown, Ambroxol for Parkinson disease with GBA1 mutation (2021)
- Unknown, Ambroxol and the GBA1 gene: The beginning of a new therapeutic era (2020)